| H01609 | |
| H number | H01609 |
| Name | Insomnia |
| Description | Insomnia is a common disorder with a prevalence of about 10% in the general population. The most common complaints related to insomnia are difficulty initiating sleep (sleep-onset insomnia), difficulty maintaining sleep due to prolonged nocturnal awakenings (sleep-maintenance insomnia), early morning awakenings, and excessive daytime sleepiness resulting from lack of sleep. Furthermore, insomnia is associated with an increased risk of anxiety and depression, suicidality, and cardiovascular diseases. Currently, cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line therapy. While behavioral therapies are effective for chronic insomnia in some patients, pharmacotherapy is frequently used when immediate short-term symptom relief is needed. The most effective pharmacologic therapies for insomnia are benzodiazepines, benzodiazepine-receptor agonists, melatonin-receptor agonists, and antidepressants. |
| Category | Nervous system disease |
| Network | - |
| Gene | - |
| Pathogen | - |
| Env factor | - |
| Carcinogen | - |
| Drug | Diphenhydramine hydrochloride [DR:D00669] Doxepin hydrochloride [DR:D00814] Phenobarbital sodium [DR:D00701] Secobarbital sodium [DR:D01310] Estazolam [DR:D00311] Triazolam [DR:D00387] Temazepam [DR:D00370] Quazepam [DR:D00457] Zolpidem tartrate [DR:D00706] Zaleplon [DR:D00530] Eszopiclone [DR:D02624] Ramelteon [DR:D02689] Suvorexant [DR:D10082] Lemborexant [DR:D11022] Daridorexant hydrochloride [DR:D11887] |
| Comment | - |
| Other DBs | ICD-11: 7A00 7A01 ICD-10: F51.0 G47.0 MeSH: D007319 |
| Reference | PMID:26414893 AUTHORS Lancee J, van Straten A, Morina N, Kaldo V, Kamphuis JH TITLE Guided Online or Face-to-Face Cognitive Behavioral Treatment for Insomnia: A Randomized Wait-List Controlled Trial. JOURNAL Sleep 39:183-91 (2016) DOI:10.5665/sleep.5344 PMID:27198954 AUTHORS Palagini L, Faraguna U, Mauri M, Gronchi A, Morin CM, Riemann D TITLE Association between stress-related sleep reactivity and cognitive processes in insomnia disorder and insomnia subgroups: preliminary results. JOURNAL Sleep Med 19:101-7 (2016) DOI:10.1016/j.sleep.2015.10.020 PMID:16750462 AUTHORS Najib J TITLE Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. JOURNAL Clin Ther 28:491-516 (2006) DOI:10.1016/j.clinthera.2006.04.014 PMID:27253658 AUTHORS Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA TITLE Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. JOURNAL J Clin Psychopharmacol 36:314-23 (2016) DOI:10.1097/JCP.0000000000000516 PMID:26438969 AUTHORS Cardinali DP, Golombek DA, Rosenstein RE, Brusco LI, Vigo DE TITLE Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse. JOURNAL Pharmacol Res 109:12-23 (2016) DOI:10.1016/j.phrs.2015.08.016 PMID:18463341 AUTHORS Passarella S, Duong MT TITLE Diagnosis and treatment of insomnia. JOURNAL Am J Health Syst Pharm 65:927-34 (2008) DOI:10.2146/ajhp060640 PMID:26940892 AUTHORS Morin CM, Edinger JD, Krystal AD, Buysse DJ, Beaulieu-Bonneau S, Ivers H TITLE Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial. JOURNAL Trials 17:118 (2016) DOI:10.1186/s13063-016-1242-3 |